HPV Vaccination Schedule Change for Children, Adolescents

Article

The Centers for Disease Control and Prevention (CDC) has changed recommendations on the human papillomavirus (HPV) vaccine schedule in 11- and 12-year-old children from 3 doses to 2 doses in at least 6-month intervals.

The Centers for Disease Control and Prevention (CDC) has changed recommendations on the human papillomavirus (HPV) vaccine schedule in 11- and 12-year-old children from 3 doses to 2 doses in at least 6-month intervals. The recommendation for three vaccines remains in effect for those beginning the vaccination series from ages 15 through 26; yet the 13- to 14-year-old group is now able to receive only 2 doses of the vaccine as well.1

This change was made due to the Advisory Committee on Immunization Practice’s (ACIP) review of current literature, reporting an immune response similar or higher in the ages 9-14 group when compared to the 16- to 26-year-old group of immunized adolescents.

“Safe, effective, and long-lasting protection against HPV cancers with two visits instead of three means more Americans will be protected from cancer,” said CDC Director Tom Frieden, MD, MPH. “This recommendation will make it simpler for parents to get their children protected in time.”

This change is reflected in the October 7, 2016, US Food and Drug Administration (FDA) approval of a 2-dose administration schedule of Gardasil® 9 (9-valent HPV vaccine) for children ages 9 through 14.

Counseling will be provided to parents from the CDC and ultimately healthcare providers on these new recommendations.

Do you feel that this new dosing schedule will improve vaccine compliance?

References:

1. Centers for Disease Control and Prevention. CDC recommends only two HPV shots for younger adolescents. 2016 Oct 19.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content